Phone: 203-752-0808
Fax: 203-752-0882
Website: http://www.carigent.com

Contact(s)
Seth Feuerstein. M.D., J.D., President - info@carigent.com

General Information
Carigent Therapeutics, Inc. is a privately held biotechnology firm located in New Haven, CT, dedicated to the development of next generation therapeutics and diagnostic agents using a propriety drug delivery platform developed by the company's scientific co-founders and licensed through Yale University.

Research Activities
Carigent Therapeutics has developed a novel technolgoy for attaching very high densities of application-specific molecules to the surfaces of biodegradable, polymeric particles ranging in size from tens of nanometers to hundreds of microns. The versatility of the platform enables the display of sophisticated combinations of ligands, adding new functionalities to biodegradable polymeric particles that to date have included increased circulation times as well as cell, tissue, and organ-specific targeting. These surface modificaitons have proven to be robust, providing long-lasting presentation of ligands in a number of in vivo applications.

Combining the benefits of controlled release, targeted delivery, and long-lasting high density surface functionalities position this technology as a premier drug delivery vehicle in a range of clinical therapeutic and diagnostic applications for cancer, cardiovasular, autoimmune and alloimmune disease.

Other Information
Ownership: private
CT Employees: 6

Back